Evidence map›Paper›PMID 36824288›Full record

ArticleInternational journal of pharmaceutics: X2023

The effect of exhalation before the inhalation of dry powder aerosol drugs on the breathing parameters, emitted doses and aerosol size distributions.

Árpád Farkas, Gábor Tomisa, Szilvia Kugler, Attila Nagy, Attila Vaskó, Erika Kis, Georgina Szénási, Gabriella Gálffy, Alpár Horváth

Open access · goldAbstract read
In one paragraph

Article in International journal of pharmaceutics: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Árpád FarkasCentre for Energy Research, Konkoly Thege M. út 29-33, 1121 Budapest, Hungary.
Gábor TomisaChiesi Hungary Kft., Dunavirág utca 2, 1138 Budapest, Hungary.
Szilvia KuglerCentre for Energy Research, Konkoly Thege M. út 29-33, 1121 Budapest, Hungary.
Attila NagyWigner Research Centre for Physics, Konkoly Thege M. út 29-33, 1121 Budapest, Hungary.
Attila VaskóPulmonology Clinic, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary.
Erika KisBabes-Bolyai University, Hungarian Department of Biology and Ecology, Cluj-Napoca, Romania.
Georgina SzénásiChiesi Hungary Kft., Dunavirág utca 2, 1138 Budapest, Hungary.
Gabriella GálffyCounty Institute of Pulmonology, Department of Pulmonology, Munkácsy M. u. 70, 2045 Törökbálint, Hungary.
Alpár HorváthChiesi Hungary Kft., Dunavirág utca 2, 1138 Budapest, Hungary.
Centre for Energy Research · HUBabeș-Bolyai University · ROUniversity of Debrecen · HUWigner Research Centre for Physics · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Airway deposition of aerosol drugs is highly dependent on the breathing manoeuvre of the patients. Though incorrect exhalation before the inhalation of the drug is one of the most common mistakes, its effect on the rest of the manoeuvre and on the airway deposition distribution of aerosol drugs is not explored in the open literature. The aim of the present work was to conduct inhalation experiments using six dry powder inhalers in order to quantify the effect of the degree of lung emptying on the inhalation time, inhaled volume and peak inhalation flow. Another goal of the research was to determine the effect of the exhalation on the aerodynamic properties of the drugs emitted by the same inhalers. According to the measurements, deep exhalation before drug inhalation increased the volume of the inhaled air and the average and maximum values of the inhalation flow rate, but the extent of the increase was patient and inhaler specific. For different inhalers, the mean value of the relative increase in peak inhalation flow due to forceful exhalation was between 15.3 and 38.4% (min: Easyhaler®, max: Breezhaler®), compared to the case of normal (tidal) exhalation before the drug inhalation. The relative increase in the inhaled volume was between 36.4 and 57.1% (min: NEXThaler®, max: Turbuhaler®). By the same token, forceful exhalation resulted in higher emitted doses and smaller emitted particles, depending on the individual breathing ability of the patient, the inhalation device and the drug metered in it. The relative increase in the emitted dose varied between 0.2 and 8.0% (min: Foster® NEXThaler®, max: Bufomix® Easyhaler®), while the relative enhancement of fine particle dose ranged between 1.9 and 30.8% (min: Foster® NEXThaler®, max: Symbicort® Turbuhaler®), depending on the inhaler. All these effects and parameter values point toward higher airway doses due to forceful exhalation before the inhalation of the drug. At the same time, the present findings highlight the necessity of proper patient education on the importance of lung emptying, but also the importance of patient-specific inhaler-drug pair choice in the future.

Indexed as

Aerosol drug deliveryAF, aerosolized fractionBMI, body mass indexBreathing parametersCAD, computer aided designCOPD, chronic obstructive pulmonary diseaseCT, computed tomographyDPI, dry powder inhalerDry powder inhalersED, emitted doseFEV1, expiratory volume at the end of the first second of forced exhalationFPF, fine particle fractionFVC, forced vital capacityGSD, geometric standard deviationICS, inhalation cortico-steroidInhalation therapyIVC, inspiratory vital capacityIVdev, inhaled volume through an inhalation deviceIV, inhaled volumeLABA, long-acting beta-agonistLung emptyingMMAD, mass median aerodynamic diameterPEF, peak expiratory flowPIFdev, peak inhalation flow through an inhalation devicePIF, peak inhalation flowPIL, patient information leafletQdev, mean inhalation flow rate through an inhalation deviceQ, mean inhalation flow rateSPC, summary of product characteristicstin-dev, inhalation time through an inhalation devicetin, inhalation time

Identifiers

PMID36824288
PMCPMC9941374
OpenAlexW4319223173

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.